D espite ongoing advances in percutaneous revascularization, coronary artery bypass grafting (CABG) continues to be performed in a large number of patients, with Ͼ400 000 operations reported in 2007 in the United States alone. 1 Although arterial conduits are generally preferred, saphenous vein grafts (SVGs) continue to be used regularly. First described by Riahi and colleagues 2 in 1975, aneurysmal dilatation of aortocoronary SVGs remains a rare yet widely reported phenomenon. Indeed, subsequent literature on the topic consists almost exclusively of case reports and small case series. Thus, the precise incidence of aortocoronary SVG aneurysms (SVGAs) remains difficult to ascertain, although in 1 case series, an incidence of 0.07% was estimated from a review of Ͼ5500 grafts at a single institution. 3 However, this likely underestimates the true number because SVGAs often remain clinically silent and no guidelines exist to screen for their development. Given the infrequent identification of SVGAs, our current understanding of the epidemiology and pathogenesis of these aneurysms remains limited.
Aneurysms are generally defined as a focal dilatation of vessels Ͼ1.5 times the proximal reference diameter; however, aneurysmal dilatation of aortocoronary SVGs has led to "giant" aneurysm formation, with reports of cases exceeding 10 cm. 4 -6 SVGAs are often incidentally identified on imaging, but cases of rupture, 7 fistula formation with neighboring anatomy, 8 and hemodynamic compromise resulting from compression of adjacent cardiac and vascular structures have been reported. 9 To date, 2 reviews have been published that briefly summarize 108 cases of SVGAs. 10, 11 Traditionally, their management has been surgical-generally resection of the aneurysm with or without bypass of the affected territory. However, with refinement of percutaneous techniques, including the use of Amplatzer devices, covered stents, and arterial coiling, the management options for affected patients are becoming increasingly diverse, and consensus on the optimal approach to managing SVGAs remains unclear.
Therefore, we performed a systematic review of published cases as has been reported for other very rare clinical conditions to determine the natural history and management of SVGAs. 12, 13 Details regarding the methodology, search strategy, and results can be accessed in the online-only Data Supplement. Briefly, 168 articles reporting 209 patients with 229 SVGAs were identified ( Figure 1 ) and analyzed ( Table I in the online-only Data Supplement).
Interestingly, although the first SVGA case was reported in 1975, 2 of the 168 articles (209 cases) published as of 2010, only 19 articles (26 cases) were published before 1990. In contrast, more than one third of available reports (73 cases) were published after December 2005. This increased reporting in recent years remains to be fully explained, and although many reasons have been postulated, it is likely that none alone fully accounts for the trend. However, given the improving long-term outcomes of patients after CABG 14 and the increasing sophistication and use of diagnostic investigations, [15] [16] [17] it is likely that a growing number of patients with SVGAs and their associated complications will continue to be identified.
Etiology
The mechanism responsible for aneurysmal dilatation of aortocoronary SVGs is poorly understood, although several pathophysiologies have been proposed. Late aneurysm formation (ie, Ͼ5 years after CABG) is thought to occur secondary to SVG atherosclerotic degeneration. This process contributes to weakening of the vessel wall, leading to graft dilatation. 11, 18, 19 However, the transposition of a vein into arterial circulation represents a unique setting in which additional factors may exacerbate and accelerate these processes. One such potential factor is vessel wall ischemia, which can occur after disruption of the vasa vasorum during the harvesting and grafting process. Some authors have also suggested that the abrupt change in wall stress when the graft is subjected to the high pressure and pulsatile flow of an arterial system may play a role in aneurysm formation. 20 However, the delayed presentation and low incidence of these lesions suggest that arterial pressures alone unlikely contribute significantly to aneurysm formation. Rather, atherosclerotic changes, graft endothelial dysfunction, and changes in medial smooth muscle cell orientation in the vicinity of valve sites likely play more pivotal roles in late aneurysm development. 21, 22 Conversely, early SVGAs have been reported within a matter of months after surgery, 2,23-25 with 1 case detected 16 days postoperatively. 26 These early aneurysms (ie, identified Ͻ12 months after surgery) undoubtedly occur secondary to a different pathophysiology. Infection of the implanted graft 26 ; intrinsic weakness of the venous wall (ie, undetected varicosities) 23 ; and technical factors relating to conduit harvesting, preparation, and grafting, including conduit injury with or without dissection, 27, 28 anastomotic suture disruption, 29 and failure to reverse the SVG at the time of grafting, 21 have been implicated in the formation of early SVGAs. Indeed, early and late SVGAs seem to be the products of unique pathophysiologies that give rise to similar clinical entities.
Patient Demographics and Clinical Presentation
SVGAs typically arise remotely from the initial bypass surgery, being identified an average of 13 years after CABG. In fact, in only 4.2% of patients were SVGAs diagnosed within the first year after CABG, with 6.1% subsequently identified between 1 and 5 years, 21.2% between 5 and 10 years, and 68.5% at Ͼ10 years after surgery. Although SVGAs were detected in both men and women on average within the sixth decade of life, SVGAs are reported predominantly in men, who account for 87% of cases, likely relating to the higher incidence of atherosclerotic coronary disease in that population (Table 1 ). 30 Patients with SVGAs have varied clinical presentations but have most commonly presented with chest pain/angina (46.4%), followed by shortness of breath (12.9%) and myocardial infarction (7.7%). However, nearly a third of reported cases of SVGAs were discovered incidentally, often first noted as abnormalities on routine chest x-rays or posthumously identified on autopsy. In contrast, few patients have been reported to present with shock or hemoptysis (4.3% and 3.8% of patients, respectively). All other presentations have been noted in Ͻ3% of identified patients ( Figure 2 ). In keeping with this observation, the majority of patients with SVGAs were hemodynamically stable at presentation (55%), although nearly 10% were unstable with the remainder of reports providing insufficient details to determine hemodynamic stability ( Table 1) .
Aneurysm Characteristics and Natural History
In reported cases of SVGAs, the mean aneurysm size at diagnosis was large at 60.4 mm, with the subset of cases specifically reporting pseudoaneurysms documenting even larger dimensions, averaging 68.9 mm (Table 1) . However, although larger aneurysms may elicit greater concern and serve as an impetus for intervention, whether SVGAs continue to increase in size once identified and the nature of the relationship between aneurysm dimensions and adverse events have thus far remained unexamined. We therefore identified all publications that serially reported SVGA size during follow-up. Nearly all such cases share the common finding of aneurysmal growth. 6, 15, 23, In fact, SVGA growth has resulted in appreciable increases in size in as little as 6 months. 37 In our institution, for instance, 1 graft aneurysm can be seen growing in size from 2 to Ͼ8 cm in 4 years ( Figure 3D -3F). However, although SVGA growth is commonly reported, the rates of growth appear to vary greatly. Indeed, in the 9 cases reporting detailed size assessments over time, considerable variation in the rates of growth can be seen ( Figure 4A ). 23, 37, 43, 44, 49, 55, 56, 58 Aneurysmal conduits have been most commonly grafted to the right coronary artery (38%), followed by the left anterior descending (25.3%), obtuse marginal (10.9%), and left circumflex (10.5%) arteries. This predominance of aneurysms in SVGs to the right coronary distribution is intriguing. One potential explanation for this finding relates simply to an increased frequency of the use of SVGs to this coronary. Indeed, left internal thoracic arterial conduits are preferentially grafted to the left anterior descending artery when used, which may lead to a relative overrepresentation of grafts to the right coronary artery. Furthermore, bilateral internal thoracic arteries tend to be used more often on the left coronary system. 60 However, given the limited information provided in the case reports on patient anatomy, it is impossible to quantify the frequency with which venous versus arterial conduits were used to graft each coronary territory. Another hypothesis for this imbalance relates to intraoperative technical considerations. The right coronary artery is often deliberately grafted first and, because of size-matching considerations, with the most proximal piece of vein and therefore the largest segment of the harvested conduit. Thus, at baseline, the segment of vein grafted to the right coronary artery will usually have the largest luminal diameter. On being exposed to arterial pressures, a larger luminal diameter will lead to greater wall tension as per Laplace's law. Thus, it stands to reason that if larger vein conduits are used preferentially as grafts to the right coronary artery, this may in part explain the increased frequency of aneurysms in this distribution. Overall, however, although an interesting observation, the explanation for this finding is likely multifactorial and the discussion of these potential mechanisms remains speculative.
Because of their size and proximity to intrathoracic structures, SVGAs causing mechanical complications are well described in the literature, being reported in 35.9% of cases. Furthermore, likely because of the predominance of SVGAs to the right coronary distribution, right-sided cardiac struc- tures have been most commonly affected. For example, right atrial compression has been documented in 11.5% of cases, right ventricular compression in 7.2%, and fistula formation in 7.7% (more than half of which formed between the SVG and the right atrium). Aneurysm rupture, the most feared complication of SVGAs, has been reported as a presenting feature in only a minority of cases; however, it remains an important complication, given its poor prognosis (Table 1) . As with aneurysms in other vascular beds, there appears to be a positive relationship between SVGA size and adverse events. There was no safe size for SVGAs below which surveillance alone can be proposed, with aneurysms measuring as little as 20 mm being associated with a 33.3% event rate of a composite end point of mechanical complications, myocardial infarction, aneurysm rupture, and/or death in cases of conservative management, which increased to as high as 69.2% for diameters exceeding 100 mm. Interestingly, this increased risk was driven predominantly by an increased risk of mechanical complications (not myocardial infarction, rupture, or death; Figure 4B ). Thus, as with other vascular aneurysms, SVGAs appear to continue to increase in size and at larger sizes portend an increased risk of compli-cations. Given that event rates even with smaller aneurysm sizes are high, these findings have clear implications for surveillance and management.
Diagnostic Assessment
The goals of imaging suspected SVGAs should be to confirm the diagnosis, to establish the size of the aneurysm, and to rule out common complications such as fistulization, compression of adjacent structures, and/or rupture. Furthermore, clinicians should evaluate the patency of the affected conduit and/or other grafts and the status of the native coronaries and assess for other indications for cardiac surgery (eg, significant valvular disease). This is of particular importance given the emerging role of percutaneous interventions for SVGAs because clinicians may be able to identify candidates suited for less invasive management. In our review of the literature, a number of diagnostic imaging modalities were used to evaluate SVGAs. Two thirds of cases (66.5%) incorporated cardiac catheterization for diagnosis and/or management planning. Similarly, computed tomography (CT) was widely used, with 60.3% of patients undergoing CT studies with or without contrast and only 12.9% using magnetic resonance imaging. Chest x-rays were reported in 54.1% of cases, although in many instances, they were performed for unrelated investigations and were not diagnostic. Echocardiograms (both transthoracic and transesophageal) were documented in only 28.2%.
Although there is no consensus on the optimal approach to the assessment of SVGAs, as reported above, the use of coronary angiography is highly prevalent in the literature. However, despite few reports explicitly addressing the limitations of specific imaging modalities, a small number have described difficulties in diagnosing and/or delineating SV-GAs via this modality because of the presence of intraluminal thrombi. 52, [61] [62] [63] For instance, in 1 case, the aneurysm was shown to compress both the right atrium and right ventricle through the use of echocardiography, although coronary angiography showed no evidence of an SVGA. It was subsequently confirmed on CT, however, and at surgery was found to measure 12ϫ10ϫ6.5 cm. 64 Similarly, echocardiography has limitations in that not all SVGAs can be properly imaged, depending on their location, with several reports describing their misdiagnoses as intracardiac masses with the technique. [65] [66] [67] Therefore, given the potential limitations of coronary angiography and echocardiography, a crosssectional modality such as CT or magnetic resonance imaging should be used in the initial assessment to definitively establish the presence of an SVGA and to assess for mechan-ical complications. Furthermore, with the increasing proficiency of coronary CT angiography, information on native and graft vessel anatomy may be derived in some instances without catheterization (Figure 2A and 2B ). 68 In most instances, echocardiography would be indicated to assess left ventricular function and to rule out concomitant valvular heart disease.
From our review, it therefore seems prudent to use a multimodality approach when investigating SVGAs to fully assess their true dimensions, to rule out complications, and to establish the underlying cardiac status of the patients affected.
Management Approaches and Outcomes
Because of the infrequent detection of SVGAs, approaches to the management of these lesions have thus far been derived primarily from case reports or small case series. Dieter et al 3 retrospectively reviewed 13 patients with SVGAs, of which 2 were treated surgically and 11 were managed conservatively. The authors concluded that early surgical treatment of SV-GAs did not result in improved short-term survival compared with conservative management. Subsequently, Sareyyupoglu et al 69 retrospectively reviewed 16 patients who underwent surgical SVGA repair and proposed that surgical revascularization should be recommended for symptomatic patients, for patients with SVGAs of diameters exceeding 1 cm, or if graft flow is diminished. Finally, Memon et al 11 recommended surgical resection and revascularization but stated that coil embolization was a viable option in cases of high surgical risk.
A review of the literature indicates that the most commonly reported management of SVGAs is surgical (58.4% of all cases), with either aneurysmal resection or ligation performed, followed by bypass grafting in cases with significant myocardium in jeopardy. Percutaneous intervention (with coil embolization, Amplatzer vascular occlusion, or covered stent placement) was reported in only 15.8% of cases, most of which were published within the last 10 years. Interestingly, conservative management was used in 20.1% of reports.
Despite a large proportion of SVGAs being identified incidentally, the in-hospital and/or 30-day mortality rate in the overall cohort was high at 13.9% (Table 1) . Individually, mortality rates for reported cases of surgical, percutaneous, and conservative management were 13.9%, 6.1%, and 23.8%, respectively ( Table 2 ). As described above, it is important to note that adverse outcomes occurred in one third of cases of SVGAs measuring Յ20 mm, rendering it impossible to propose a "safe" size for SVGA surveillance.
Our review suggests that both percutaneous and surgical interventions are viable management options for SVGAs. Additionally, with the advent and development of percutaneous methods, minimally invasive interventions are gaining popularity. Our findings suggest that once SVGAs are identified, clinicians must balance the risks of observation with those of intervention and be cognizant that SVGAs can be expected to continue to increase in size. However, if conservative management is preferred, our results support the notion that smaller SVGAs can be monitored more safely than their larger counterparts. 
Management Algorithm
Although comparative studies are not possible, the observed low mortality rate for percutaneous options is encouraging in light of the high risk of repeat sternotomy 70 (Table 3) . Given the emerging role of percutaneous management of SVGAs, both anatomic features and patient factors should be considered in the selection of the optimal intervention. If possible, we propose that patients should be assessed by a heart team comprising a cardiac surgeon and an interventionalist with experience in structural heart disease. In patients with alternative indications for cardiac surgery (ie, multiple territories requiring revascularization or concomitant valve surgery), surgical intervention should be pursued. However, in the absence of these alternative indications, we have proposed a management algorithm ( Figure 5 ).
The first step in deciding on management options for SVGAs is to assess for the presence of mechanical compli-cations. The presence of fistula, rupture, or compression of adjacent cardiac or vascular structures renders surgery the only option, and aneurysm resection with subsequent bypass should be performed when technically feasible. However, the majority of patients present without mechanical complications, and in these individuals, the patency of the affected vein graft should be established. In cases in which the affected graft remains patent despite aneurysmal dilatation, percutaneous management with a covered stent in patients with suitable anatomy offers a less invasive approach while maintaining myocardial perfusion. In this select group, distal embolization protection is indicated to prevent embolization of thrombus, [72] [73] [74] with successful stenting permitting exclu- *Includes 1 case using a "homemade" covered aortic endograft. 34 †Comprises 1 case of ethylene-vinyl alcohol copolymer injection, 55 1 case using both a covered stent and coil embolization, 71 and 1 case using coil embolization and an Amplatzer vascular plug. 36 ‡Based on 10 cases in which data were available. §Based on 6 cases in which data were available. Based on 2 cases in which data were available. sion of the aneurysm. 75 In patients with patent affected grafts in whom the graft anatomy is not favorable to covered stenting, surgical resection with repeat bypass grafting should be pursued. In a large number of patients, the affected graft is occluded with proximal patency and persistent flow into the aneurysmal segment (Figure 3H and Movies I and II in the online-only Data Supplement). 76 In this subset, preservation of myocardial blood supply is not a concern. Similarly, in patients in whom the affected graft supplies a small territory, the aneurysm neck can be occluded by Amplatzer vascular plugs 77 ( Figure 3I and Movie III in the online-only Data Supplement) or the aneurysm can be thrombosed by endovascular coiling. 9, 44 In patients with moderate or large territories supplied by the affected graft, there may be a role for the assessment of myocardial viability. Patients with scar in the territory supplied by the culprit SVG will not benefit from revascularization, 78 and percutaneous closure of the aneurysm could be considered. Conversely, those with viable myocardium may benefit from revascularization, particularly in cases of large viable territories. 79 Numerous studies have demonstrated that the use of fluorodeoxyglucose positron emission tomography, cardiac magnetic resonance imaging, dobutamine stress echocardiography, or single-photon emission CT imaging to detect hibernating myocardium can help predict recovery of regional function with revascularization. 80 Thus, viability testing may enable the selection of patients in whom the affected SVG supplies predominantly viable myocardium and who thus may benefit from repeat revascularization. Of course, in patients in whom repeat surgical intervention is not an option because of comorbidities or patient wishes, percutaneous closure of the SVGA remains the preferred choice.
Limitations
Ideally, evidence for optimal investigation and management strategies for patients with SVGAs would be derived from randomized, controlled trials or large cohort studies, yet given the rarity of the condition, it is unlikely that such a study would be feasible. Thus, we performed the current systematic review to summarize the available knowledge on this rare clinical entity. We acknowledge that such an approach has potential limitations in that it is retrospective and comprises individual case reports and small case series. Thus, reporting bias may influence the available cases for analysis, particularly because adverse outcomes after novel interventions or any type of outcome after commonly used therapies such as surgical treatment may be less likely to be reported. In addition, given the lack of routine screening for SVGAs, symptomatic patients may be relatively overrepresented in the literature because they are arguably more likely to be investigated. Furthermore, the lack of both patient randomization to their interventions and standardized reporting of baseline characteristics precludes a comparative analysis of outcomes based on management strategies. Despite these limitations, a systematic review of cases represents the only available method to evaluate SVGAs and provides clinicians with the best available evidence on which to base their clinical decisions.
Conclusions
SVGAs represent a rare and typically late complication of CABG with the potential for significant morbidity and mortality. Our analysis suggests that the risk of complication increases with size and that, once identified, these aneurysms continue to grow at variable rates. Multimodality imaging is often required to establish the size of the SVGA and the myocardial territory supplied by the affected graft and to assess for complications. The proposed management algorithm takes into account patient and clinical characteristics, identifying individuals best suited for percutaneous or surgical intervention on the basis of the published experience. This systematic review should help clinicians in the evaluation and management of patients presenting with SVGAs.
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